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Strengths and limitations of this study
 ► The methodology includes the use of a compre-
hensive three- pronged search strategy with no lan-
guage restrictions to identify guidelines from across 
Europe, the use of a standardised and internationally 
recognised guideline appraisal tool (AGREE II), the 
assessment of levels of evidence and strength of 
recommendations and the assessment of whether 
antibiotic stewardship, a key measure to reduce an-
timicrobial resistance (AMR), was considered.
 ► The review focused only on AOM without complica-
tions; guidelines for complex otitis media requiring 
specialist otolaryngology input were not included. 
Another limitation is the consideration of whether 
guidelines developers used country- specific AMR 
patterns to assess if the recommendations of anti-
biotics were based on AMR data. However, there is 
often wide heterogeneity in terms of AMR patterns 
within each country.
AbStrACt
Objectives To appraise European guidelines for acute 
otitis media (AOM) in children, including methodological 
quality, level of evidence (LoE), astrength of 
recommendations (SoR), and consideration of antibiotic 
stewardship.
Design Systematic review of the literature.
Data sources Three- pronged search of (1) databases: 
Medline, Embase, Cochrane library, Guidelines 
International Network and Trip Medical Database; (2) 
websites of European national paediatric associations 
and (3) contact of European experts. Data were collected 
between January 2017 and February 2018.
Eligibility criteria National guidelines of European 
countries for the clinical management of AOM in children 
aged <16 years.
Data extraction and synthesis Data were extracted 
using tables constructed by the research team. Guidelines 
were graded using AGREE II criteria. LoE and SoR were 
compared. Guidelines were assessed for principles of 
antibiotic stewardship.
results AOM guidelines were obtained from 17 or the 
32 countries in the European Union or European Free 
Trade Area. The mean AGREE II score was ≤41% across 
most domains. Diagnosis of AOM was based on similar 
signs and symptoms. The most common indication 
for antibiotics was tympanic membrane perforation/
otorrhoea (14/15; 93%). The majority (15/17; 88%) 
recommended a watchful waiting approach to antibiotics. 
Amoxicillin was the most common first- line antibiotic 
(14/17; 82%). Recommended treatment duration varied 
from 5 to 10 days. Seven countries advocated high- dose 
(75–90 mg/kg/day) and five low- dose (30–60 mg/kg/day) 
amoxicillin. Less than 60% of guidelines used a national 
or international scale system to rate level of evidence to 
support recommendations. Under half of the guidelines 
(7/17; 41%) referred to country- specific microbiological 
and antibiotic resistance data.
Conclusions Guidelines for managing AOM were similar 
across European countries. Guideline quality was mostly 
weak, and it often did not refer to country- specific 
antibiotic resistance patterns. Coordinating efforts to 
produce a core guideline which can then be adapted 
by each country may help improve overall quality and 
contribute to tackling antibiotic resistance.
IntrODuCtIOn
Acute otitis media (AOM) is one of the most 
common infections in childhood1 2; approxi-
mately 60% of children have had at least one 
episode by 4 years of age.3 It is also one of the 
most frequently cited reasons for antibiotic 
prescription in children less than 3 years of 
age,4 5 accounting for 14% of all antibiotic 
prescriptions in children in the UK.6 While 
both bacterial and/or viral pathogens can 
cause AOM,7 8 it is usually considered to be 
a bacterial complication of upper respiratory 
tract viral infection.9
The rationale for antibiotic prescrip-
tion includes symptom control10 and the 
prevention of rare but serious complica-
tions, including mastoiditis and meningitis.11 
However, studies show that up to 80% of cases 
resolve spontaneously without antibiotics,12 13 
and antibiotics are associated with the risk 
of side effects including vomiting, diarrhoea 
and rash.13 14 In addition, the inappropriate 
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use of antibiotics has been identified as one of the key 
drivers of antibiotic resistance, a global health priority.15–17 
Emerging research has also demonstrated that longer 
antibiotic courses can lead to higher risks of resistance. 
Thus, providing clear guidance on appropriate anti-
biotic use in terms of the indications, choice and dura-
tion is considered important to help reduce antibiotic 
resistance.18
To promote antibiotic stewardship, the WHO recom-
mends the development of treatment guidelines and the 
monitoring of local antibiotic resistance to inform the 
choice of antibiotics.19 National guidelines for the first- 
line management of AOM may play a vital role in antibi-
otic stewardship.20 To our knowledge, there has not been 
a systematic review of the quality and content of national 
guidelines for the management of AOM. The aim of this 
systematic review was to describe European guidelines for 
AOM in children to assess their methodological quality, 
to describe their evidence- based Strength of Recommen-
dations (SoR) and to assess whether they incorporate 
consideration of antibiotic stewardship.
MEthODOlOgy
To ensure a comprehensive review of nationally endorsed 
guidelines, we used a three- pronged approach that 
included (1) a systematic database search; (2) a website 
search of European national societies and (3) expert 
consultation.
First, a systematic search of databases was carried out 
using Medline, Embase, Cochrane library, Guidelines 
International Network and Trip Medical Database from 
April 2017 to February 2018. Search terms were a combi-
nation of synonyms for (1) acute otitis media and (2) 
guidelines. Guidelines were included if they met the 
following eligibility criteria: (1) they were pertaining to 
the management of simple AOM, excluding the manage-
ment of chronic or complex otitis media cases requiring 
specialist otolaryngology input; (2) they were national 
guidelines or endorsed by the national medical society 
from a European Union (EU) or European Free Trade 
Area (EFTA) country and (3) published from the year 
2000 to present. The American Association of Pediatrics 
(AAP)21 and the WHO22 guidelines were also included for 
comparison as they are widely recognised and used inter-
nationally. The search included all European languages. 
An initial review of titles and abstracts was performed 
by one reviewer (HS). Additionally, the bibliographies 
of all guidelines were examined to identify further rele-
vant resources (HS). Second, the websites of national 
paediatric associations listed by the European Paediatric 
Association/Union of National European Paediatric Soci-
eties and Associations were hand- searched (HS). Finally, 
a network of paediatric partners across Europe were 
contacted (RN, SY, JED and HS) to verify if the identi-
fied guidelines were the most up to date and widely used, 
and in cases where we had not managed to locate any 
guidelines, to assist in obtaining them. The choice of 
search terms and final selection of full- text guidelines was 
performed by two reviewers (HS and JED) (see online 
supplementary files 1 and 2). If multiple national guide-
lines were found, the guideline judged to be most up to 
date, comprehensive and more commonly used in clin-
ical practice was included after discussion between paedi-
atrics partners and reviewers (HS and JED). Data were 
extracted using tables constructed by the research team.
Patient and public involvement
This systematic review was performed without patient 
involvement.
guideline quality assessment
The AGREE II instrument was used independently by two 
reviewers (HS and JED) to determine the quality of each 
national guideline.23 This is a standardised instrument 
that appraises the methodological framework of guide-
line development. The six domains assessed are (1) scope 
and purpose, (2) stakeholder involvement, (3) rigour 
of development including evidence base, (4) clarity of 
presentation, (5) applicability and (6) editorial indepen-
dence. Domains were scored on a 1–7 scale; any score that 
varied by >3 out of 7 was discussed and revised if this was 
felt to be reasonable.
level of evidence and Sor
National scales for grading levels of evidence (LoE) and 
SoR were converted to Oxford Centre for Evidence Based 
Medicine (OCEBM) LoE and SoR (see online supple-
mentary files 3 and 4). However, heterogeneity between 
grading systems meant that a meaningful comparison was 
difficult. Therefore in order to compare LoE between 
guidelines, we reviewed (1) whether guidelines used a 
national/international scale of evidence, (2) whether 
principles of risk versus harm were assessed, (3) whether 
strengths and limitations of evidence were assessed and 
(4) whether evidence was linked to a SoR. To allow for 
more meaningful comparison between guidelines, we 
used our scores for AGREE II items 11, 9 and 12 for the 
above (2), (3) and (4), respectively. We converted SoR 
into three categories: highest, moderate and lowest grade, 
indicated by shading of results in tables (tables 1 and 2).
Antibiotic stewardship
As we were unable to find a standard scoring system to 
assess if a clinical guideline includes consideration of 
antibiotic stewardship, we based our methodology on 
a study by Elias et al.24 We thus proposed six principles 
that demonstrate consideration of antibiotic stewardship 
based on the authors' consensus opinion. The principles 
are the inclusion in the guideline of (1) diagnostic criteria; 
(2) criteria for initiation of antibiotic therapy; (3) dosage; 
(4) route of administration; (5) what percentage of anti-
biotic recommendations was based on country- specific 
resistance patterns (ie, if two of three recommended anti-
biotics were supported by country- specific antibiotic resis-
tance data, 67% was awarded) and (6) whether guidelines 
recommending amoxicillin or amoxicillin- clavulanic acid 
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Table 1 Strength of Recommendations supporting 
immediate or watchful waiting approach to antibiotic 
administration in European, AAP and WHO guidelines
Treatment approach
Strength of 
recommendation
Immediate antibiotics for any AOM
WHO Strong recommendation
Immediate antibiotics for any AOM can be considered
Finland A
USA Recommendation
Czech Republic No grade
Watchful waiting approach (except for indications outlined 
in table 2)
France A
Italy A
Spain A
Denmark √
Poland B
Portugal IIa
UK B
Belgium No grade
Germany No grade
Ireland No grade
Luxembourg No grade
The Netherlands No grade
Norway No grade
Sweden No grade
Switzerland No grade
Legend
Highest grade
Moderate grade
No grade
Note: There is no ‘Lowest grade’ in this table.
AAP, American Association of Pediatrics; AOM, acute otitis media; 
WHO, World Health Organisation.
based the dosage recommendation on country- specific 
resistance data. These two antibiotics were chosen 
because in contrast to other antibiotics, a higher dosage 
is recommended to overcome resistant strains.25
rESultS
Overview of existing guidelines
The search retrieved 7340 records (figure 1). Of these, 
19 guidelines were obtained. National guidelines were 
obtained from 17 of 32 European countries26–42 (53%) 
(figure 2) and 2 non- European countries/organisa-
tions (USA and WHO). The majority of these were 
from Western Europe and Scandinavia. The intended 
audience of the obtained guidelines was mainly general 
practitioners and paediatricians, although some included 
nurses and/or physician’s assistants. Of note, 4 of 17 
European guidelines clearly stated that they based their 
findings on other national guidelines, including those 
of the American Academy of Paediatrics, French Agence 
Française de Sécurité Sanitaire des Produits de Santé 
(now known as Agence Nationale de Sécurité du Médica-
ment et des Produits de Santé) and UK Scottish Intercol-
legiate Guidelines Network (SIGN).
Diagnostic criteria
Of note, 15 of 17 (88%) European guidelines outlined 
the signs and symptoms for diagnosing AOM (see online 
supplementary file 5) with considerable similarities 
between the guidelines. Twelve of 17 (71%) used strict 
combinations of three diagnostic criteria: (1) acute onset 
of symptoms (ie, otalgia, fever), (2) evidence of middle 
ear (ME) effusion (ie, tympanic membrane (TM) bulging 
of TM or otorrhoea on examination) and (3) inflamma-
tion of TM on examination.
Otoscopy
Examination tools including standard otoscopy were 
advised by 15 of 17 (88%) European guidelines (see 
online supplementary file 6). Pneumatic otoscopy 
(9/15; 60%) and tympanometry (7/15; 50%) were also 
recommended.
Additional investigations
No guidelines advised routine laboratory or radiographic 
investigations (see online supplementary file 7). Of note, 
9 of 17 (53%) guidelines stated specific indications for 
carrying out investigations. Eight of 9 (89%) advised 
consideration of a culture sample of the ME via tympano-
centesis, most commonly for treatment failure (6/9; 67%) 
and complications such as mastoiditis (4/9; 44%). Three 
guidelines (3/9; 33%) discussed imaging modalities such 
as a CT brain when investigating secondary mastoiditis.
Approach to antibiotic administration
There were two approaches towards antibiotic administra-
tion: a watchful waiting approach and immediate antibiotic 
prescription (table 1). Fifteen of 17 (88%) of the European 
guidelines recommended a watchful waiting approach 
where clinicians were encouraged to prescribe antibiotics 
if symptoms persisted for 1–3 days or in case of any clinical 
deterioration. TM perforation/otorrhoea (14/15; 93%) 
and severity of symptoms (13/15; 87%) were the most 
common indications for immediate antibiotic administra-
tion (table 2). WHO guidelines recommended all children 
with confirmed AOM be given antibiotics.
First-line antibiotic therapy
Of note, 14 of 17 (82%) European guidelines recom-
mended oral amoxicillin as an option for first- line treat-
ment (figure 3), of which 7/14 (50%) recommended a 
high dose (75–90 mg/kg/day) and 5/14 (36%) a low dose 
(30–60 mg/kg/day). Stratification to high- dose or low- 
dose amoxicillin for children in the UK SIGN guideline 
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Figure 1 PRISMA systematic review flow diagram
is weight- dependent; the Irish guidelines did not specify 
a dose. All the Nordic countries (ie, Denmark, Sweden 
and Norway) except Finland included oral penicillin V 
24–75 mg/kg/day as a first- line choice (see online supple-
mentary file 8).
treatment failure and penicillin allergy: alternative antibiotic 
treatments
In case of treatment failure, per oral/intravenous 
amoxicillin- clavulanic acid (11/15; 73%) and intrave-
nous/intramuscular ceftriaxone (8/15; 53%) were the 
most commonly recommended antibiotics. In case of 
penicillin allergy, guidelines advised either oral clarithro-
mycin (8/16; 50%) or oral trimethoprim–sulfamethox-
azole (6/16; 38%) (see online supplementary file 8).
Quality assessment: AgrEE II scores
All guidelines were appraised using the AGREE II Criteria 
(table 3). In four of seven domains (ie, 2, 3, 5 and 6), 
European guidelines obtained a mean score of ≤41% 
while only two domains (ie, 1 and 4) scored above 63% 
(see online supplementary file 9a,b)
loE and Sor
Of note, 10 of 17 European guidelines (59%) based their 
certainty of evidence (ie, LoE) and SoR on a variety of 
methodologies (table 4). The only crossover was between 
Poland and Spain which used a methodology from the 
Infectious Diseases Society of America. AGREE II scores 
for quality of the LoE were variable, and approximately 
half of European guidelines (8/17; 47%) scored ≤4 
across all items. SoR was often based on study design 
(ie, multiple randomised controlled trials), but for some 
it was based on more subjective assessments (ie, ‘well- 
conducted studies’).
Antibiotic stewardship
The majority of guidelines provided diagnostic criteria for 
AOM, specifications on when to start antibiotics, the route 
of administration and the duration of treatment (table 5). 
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Figure 2 European AOM guidelines (lead group and year 
published).
Figure 3 Routine first- line antibiotics: initiation, choice, duration and Strength of Recommendation.
However, less than half referred to country- specific AMR 
patterns, and four (24%) included both country- specific 
AMR data and specified resistance levels to amoxicillin/
amoxicillin–clavulanic acid to guide local choices.
DISCuSSIOn
Approximately half of the 32 EU/EFTA countries have 
AOM guidelines. Diagnosis of AOM was based on similar 
signs and symptoms. Tympanocentesis was commonly 
reserved for treatment failure. The vast majority of Euro-
pean guidelines advocated for a watchful waiting approach 
to antibiotic therapy with the most common indications 
for treatment being TM perforation and severity of symp-
toms. Amoxicillin was the most commonly recommended 
first- line antibiotic but with differences in terms of 
recommended duration and dosage. Our quality assess-
ment found low mean AGREE II scores of ≤41% in most 
domains. Less than 60% of guidelines used a national or 
international system to rate LoE to support recommenda-
tions. Less than half of the guidelines referred to country- 
specific patterns of AMR.
Strengths of our study include the comprehensiveness 
of our three- pronged search strategy, the use of AGREE 
II, an internationally recognised guideline appraisal tool 
and an assessment of which LoE and SoR were used. Our 
analysis also included a qualitative assessment of whether 
antibiotic stewardship was considered in the development 
of guidelines based on five criteria. In order to provide 
a broad sense on whether AMR data were considered, 
one of the criteria was whether the antibiotic recommen-
dations referred to national- level AMR data. However, 
the limitation of this is that there is often wide hetero-
geneity in AMR patterns within each country, therefore 
guidelines should ideally recommend that the antibiotic 
choice be adapted to available local AMR data. Another 
limitation is our focus on simple AOM and exclusion of 
guidelines about complex cases requiring otolaryngology 
specialist input.
Previously published works demonstrated a common 
consensus in criteria for AOM diagnosis, and that a 
watchful waiting period was the standard of care in 
Europe; amoxicillin was also found to be the most 
commonly recommended antibiotic.43–45 In comparison 
with these studies, our work aimed to compare additional 
facets of AOM management in Europe, including grading 
their quality, comparison of LoE and SoR and assessing 
their inclusion of country- specific AMR data. Zeng et 
al also used AGREE II scores to assess quality of upper 
respiratory tract infections guidelines including three 
AOM guidelines from Japan, USA and UK.46 We note a 
>10- point discrepancy in scoring in two of six domains 
between Zeng et al and ourselves for UK SIGN and US 
AAP AOM guidelines. This may indicate inter- user vari-
ability in AGREE II scoring.47 Elias et al assessed global 
infectious diseases guidelines and found that local AMR 
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Table 3 AGREE II scores (%) of European, AAP and WHO guidelines
Domain number Domain name
European mean
(range) AAP mean WHO mean
1 Scope and purpose 57 (10–100) 97 94
2 Stakeholder involvement 41 (0–92) 67 58
3 Rigour of development 34 (0–83) 88 80
4 Clarity of presentation 78 (21–100) 89 92
5 Applicability 23 (0–58) 35 60
6 Editorial independence 29 (0–96) 54 83
AAP, The American Association of Pediatrics; WHO, World Health Organisation.
Table 4 Level of Evidence in AOM guidelines
Country Grading system for LoE *
Score: 
consideration of 
benefits and harms 
(AGREE II Item 11†)
Score: strengths 
and limitations 
of the evidence 
(AGREE II Item 9)
Score: link between 
recommendations and 
evidence (AGREE II
Item 12)
Belgium INAMI 5 7 6
Czech Republic – 1 1 2
Denmark OCEBM 7 7 6
Finland Duodecim 1 6 6
France ANAES 3 1 1
Germany AWMF 6 3 3
Ireland – 1 1 1
Italy PNLG 5 5 6
Luxembourg – 3 1 2
The Netherlands – 7 7 5
Norway – 1 1 3
Poland Infectious Disease Society of America 6 3 5
Portugal European Society of Cardiology 2 2 4
Sweden – 3 3 1
Switzerland – 1 1 1
Spain Infectious Disease Society of America 5 2 7
UK SIGN 7 7 6
USA AAP 7 7 7
WHO GRADE 7 7 6
*If no LoE scale used, it is denoted by –.
†AGREE II scores: 1=no information in the guideline; 7=exceptional reporting.
AAP, The American Association of Pediatrics; ANAES, l'Agence Nationale d'Accréditation et d'Évaluation en Santé ; AOM, acute otitis media; 
AWMF, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften; GRADE, Grading of Recommendations, Assessment, 
Development and Evaluations; INAMI, Institut National d'Assurance Maladie- Invalidité; LoE, level of evidence; OCEBM, Oxford Centre for 
Evidence Based Medicine; PNLG, Programma Nazionale Linee Guida; SIGN, Scottish Intercollegiate Guidelines Network.
patterns were taken into account in 50%–75% of recom-
mendations which is similar to our findings.
The development of clinical guidelines according to 
the high standards of the AGREE II criteria is a resource 
- intensive exercise and this may be one of the reasons why 
we did not identify any guidelines from some countries. 
Many guidelines in this study received low AGREE II scores. 
Many of the resource- intensive initial steps in guidelines 
development are universal, for example defining the 
objectives, the clinical questions, the target populations 
of patients and end users and designing a comprehen-
sive search strategy to identify relevant evidence from 
the literature, a process to appraise the evidence, a way 
to present recommendations unambiguously and strate-
gies to successfully implement guidelines. Replicating this 
process in each country to reach similar conclusions does 
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not seem necessary nor efficient, and it may make sense 
for these or some of these processes to be undertaken by a 
core group of experts from across Europe. This is already 
the case for other medical specialities, for example the 
European Joint Task Force for cardiovascular disease 
prevention provides guidelines that can be used across 
Europe.48 The centrally developed guidelines could then 
be adapted in each country for recommendations, such 
as choice of antibiotics, which depends on local AMR 
patterns and immunisation coverages against the main 
pathogens causing AOM. This implies the implementa-
tion of robust epidemiological and standardised AMR 
surveillance systems in each country which is currently 
underway with the support of international initiatives 
such as the European Centre for Disease Prevention and 
Control surveillance systems,49 and the WHO Global 
Antimicrobial Resistance Surveillance System.50 Other 
aspects that could lead to local adaptation could be local 
care pathways, and user and patient preferences. This 
approach would allow the development of guidelines of 
better quality and better adapted to local contexts, and it 
might contribute to reducing the spread of AMR.
COnCluSIOn
Review of guidelines reveals major similarities in AOM 
management recommendations across Europe. Existing 
European guidelines scored poorly in most AGREE II 
domains, including items related to how evidence was gath-
ered and appraised. Consideration of country- specific anti-
biotic resistance patterns appears to be limited. Centrally 
produced guidelines adapted for local care pathways, user 
and patient preferences, and for local antimicrobial resis-
tance patterns may provide more targeted recommenda-
tions, reduce unnecessary antibiotic administration and 
help reduce the spread of antibiotic resistance.
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